Clinical behavior of a cohort of adult women with facial acne treated with combined oral contraceptive: ethinylestradiol 20 µg/dienogest 2 mg
article
OA: gold
CC0
Abstract
Acne vulgaris is the most common skin disease. It affects the young adult female population and generates great impact on physical and mental health. One of the treatments with good results for affected women is combined oral contraceptive pills (COCPs). The aim of this study was to determine the clinical effect of facial acne management with ethinylestradiol 20 µg/dienogest 2 mg in a cohort of Colombian adult women. A cohort of 120 female university students was followed for 12 months. These participants were enrolled in the Sexual and Reproductive Health Program of the Santiago de Cali University. This cohort admitted women between 18 and 30 years old who had chosen to start birth control with ethinylestradiol 20 µg/dienogest 2 mg COCPs, did not have contraindi cations to the use of COCPs, and had been diagnosed with acne. Monthly monitoring of facial acne lesion count was performed. Relative changes in facial lesion count were identified. At the end of follow-up, the percentage of reduction of lesions was 94% and 23% of women had a 100% reduction in acne lesions. In conclusion, the continued use of the ethinylestradiol 20 µg/dienogest 2 mg COCPs reduced inflammatory and non-inflammatory acne lesions in reproductive-age women between 18 and 30 years of age with no severe acne.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (33)
- Clinical findings with the oral contraceptive combinationethinylestradiol/dienogest in poland via openalex
- Dienogest via openalex
- Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate via openalex
- Ethinylestradiol/Dienogest in Oral Contraception via openalex
- Hormone withdrawal-associated symptoms: Comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate via openalex
- Progestogens with Antiandrogenic Properties via openalex
- doi:10.1111/jdv.13186 via openalex
- doi:10.1016/0010-7824(96)00005-4 via openalex
- doi:10.1136/bmj.i2002 via openalex
- doi:10.1016/j.jaad.2015.12.037 via openalex
- doi:10.1002/14651858.cd003989.pub5 via openalex
- doi:10.1136/bmj.f5298 via openalex
- doi:10.1002/14651858.cd004425.pub6 via openalex
- doi:10.1111/jdv.13188 via openalex
- doi:10.2307/2285889 via openalex
- doi:10.1111/bjd.12149 via openalex
- doi:10.1111/jdv.12061 via openalex
- doi:10.1111/bjd.13681 via openalex
- W6638148417 via openalex
- W6658296803 via openalex
- W6685411912 via openalex
- W6694886308 via openalex
- W6799852768 via openalex
- doi:10.1111/bjd.13462 via openalex
- doi:10.1016/j.ejogrb.2010.12.027 via openalex
- doi:10.4103/0019-5154.131455 via openalex
- doi:10.1002/14651858.cd004425.pub5 via openalex
- doi:10.1016/j.jaad.2014.03.051 via openalex
- doi:10.1016/j.ad.2012.05.004 via openalex
- doi:10.1111/j.1468-3083.2011.04374.x via openalex
- doi:10.1016/j.pop.2015.07.007 via openalex
- doi:10.1016/j.adengl.2012.05.021 via openalex
- doi:10.1002/14651858.cd003989.pub2 via openalex
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-05-11T06:35:44.859312+00:00
License: CC0
· commercial use OK